ZUPLENZ

Peak

ondansetron

NDAORALFILM
Approved
Jul 2010
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20

Clinical Trials (5)

NCT05265507Phase 4Unknown

Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron

Started Mar 2022
NCT03555188Phase 3Completed

TReatment of Irritable Bowel Syndrome With Diarrhoea Using Titrated ONdansetron Trial

Started Mar 2018
80 enrolled
IBS - Irritable Bowel Syndrome
NCT02614586Phase 1Terminated

Evaluation of TAK-058 and Ondansetron on P50 Auditory Gating in Participants With Stable Schizophrenia

Started Dec 2015
11 enrolled
Schizophrenia
NCT02519842Phase 3Terminated

Efficacy and Safety Study of Fosaprepitant (MK-0517) Plus Ondansetron Versus Ondansetron Alone for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Pediatric Participants (MK-0517-044)

Started Sep 2015
75 enrolled
Chemotherapy-induced Nausea and Vomiting
NCT01450826Phase 2Completed

Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide

Started Jun 2014
136 enrolled
NauseaVomitingGlioma

Loss of Exclusivity

LOE Date
Jul 13, 2030
53 months away
Patent Expiry
Jul 13, 2030

Patent Records (2)

Patent #ExpiryTypeUse Code
8580830
Nov 23, 2029
Product
—
9095577
Jul 13, 2030
Product
—
External Resources
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers